siFga impairs clot stability ex vivo but does not increase bleeding risk. (A) Representative TEG curve comparing clotting of whole blood from mice treated with siFga (blue) or siLuc (red) 1 week prior. (B-D) Quantifying TEG data such as from panel A to determine clot time (B), rate of clot formation (C), and maximum clot amplitude (D) (n = 4-5). (E) Mice were injected with PBS (green) or siFga (blue) 1 week prior to saphenous vein puncture (n = 8). Bleeding from the saphenous vein injury was monitored for 40 minutes, and bleed time and blood loss were quantified. (F) Mice were injected with siLuc (red) or siFga (blue) 1 week prior to tail transection. Bleeding was monitored for 20 minutes, and bleed time and blood loss were quantified (n = 8). ***P < .001. ns, no significant difference. Error bars represent mean ± SEM.